| The 2016 revision of the World Health Organization classification of lymphoid neoplasms SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ... Blood, The Journal of the American Society of Hematology 127 (20), 2375-2390, 2016 | 8345 | 2016 |
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma B Coiffier, E Lepage, J Brière, R Herbrecht, H Tilly, R Bouabdallah, ... New England Journal of Medicine 346 (4), 235-242, 2002 | 6742 | 2002 |
| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3324 | 2019 |
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene G Cartron, L Dacheux, G Salles, P Solal-Celigny, P Bardos, P Colombat, ... Blood, The Journal of the American Society of Hematology 99 (3), 754-758, 2002 | 2438 | 2002 |
| Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, ... J Clin Oncol 23 (18), 4117-4126, 2005 | 1906 | 2005 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1247 | 2011 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1223 | 2014 |
| The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma KJ Savage, S Monti, JL Kutok, G Cattoretti, D Neuberg, L De Leval, ... Blood 102 (12), 3871-3879, 2003 | 1036 | 2003 |
| Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response S Monti, KJ Savage, JL Kutok, F Feuerhake, P Kurtin, M Mihm, B Wu, ... Blood 105 (5), 1851-1861, 2005 | 979 | 2005 |
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆ M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ... Annals of Oncology 32 (3), 298-308, 2021 | 936* | 2021 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 726 | 2022 |
| Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation P Colombat, G Salles, N Brousse, P Eftekhari, P Soubeyran, V Delwail, ... Blood, The Journal of the American Society of Hematology 97 (1), 101-106, 2001 | 726 | 2001 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 696 | 2019 |
| Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed C Thieblemont, F Berger, C Dumontet, I Moullet, F Bouafia, P Felman, ... Blood, The Journal of the American Society of Hematology 95 (3), 802-806, 2000 | 662 | 2000 |
| Prognostic significance of survivin expression in diffuse large B-cell lymphomas C Adida, C Haioun, P Gaulard, E Lepage, P Morel, J Briere, H Dombret, ... Blood, The Journal of the American Society of Hematology 96 (5), 1921-1925, 2000 | 625 | 2000 |
| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 619 | 2020 |
| Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) O Hermine, C Haioun, E Lepage, MF d'Agay, J Briere, C Lavignac, G Fillet, ... | 615 | 1996 |
| Diffuse large B-cell lymphoma LH Sehn, G Salles New England Journal of Medicine 384 (9), 842-858, 2021 | 610 | 2021 |
| Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience G Salles, M Barrett, R Foà, J Maurer, S O’Brien, N Valente, M Wenger, ... Advances in therapy 34, 2232-2273, 2017 | 579 | 2017 |
| Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol—a groupe d’Etude des lymphomes de l … C Haioun, E Lepage, C Gisselbrecht, G Salles, B Coiffier, P Brice, A Bosly, ... Journal of Clinical Oncology 18 (16), 3025-3030, 2000 | 577 | 2000 |
Callet-Bauchu EMCU-PH HCL在 chu-lyon.fr 的电子邮件经过验证
